Prediction of potential drug-resistant ALK mutations against fourth-generation inhibitors NVL-655 and TPX-0131
{{output}}
Anaplastic lymphoma kinase (ALK) rearrangements have been identified as oncogenic drivers of multiple malignancies. Although at least three generations of ALK inhibitors have been developed, the occurrence of drug-resistant mutations remains a major barrier to... ...
